VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. This leadership change comes as the company aims to strengthen its financial strategy and support the continued development of its proprietary BiTAC technology platform and oncology pipeline.
Willener brings more than three decades of international financial leadership experience across global capital markets, investment banking, corporate finance, asset management, and strategic leadership. Prior to joining VERAXA, he served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
In his new role, Willener will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities, and continued development of its proprietary BiTAC technology platform and oncology pipeline. The appointment underscores VERAXA's commitment to advancing its innovative antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other formats, which are powered by transformative technologies and rigorous quality-by-design principles.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company's pipeline includes ADCs and proprietary BiTAC formats, which are rapidly advancing into clinical development and beyond.
The addition of Willener to the executive team is a significant step for VERAXA as it seeks to navigate the complexities of the biotech sector and bring its therapies to market. His extensive experience in capital markets and corporate finance is expected to be instrumental in securing the resources needed to advance the company's research and development efforts.
For more information about VERAXA Biotech and its latest developments, visit the company's newsroom at http://nnw.fm/VRXA.
